Business
IM Cannabis Reschedules Fourth Quarter and Full Year 2021 Conference Call to Thursday, March 31 at 9:00 a.m. ET
TORONTO and GLIL YAM, Israel, March 29, 2022 /PRNewswire/ -- IM Cannabis Corp. (the "Company" or "IM Cannabis") (CSE: IMCC, NASDAQ: IMCC), a leading medical
About this update from Im Cannabis Corp.
[{"type":"text","content":"TORONTO and GLIL YAM, Israel, March 29, 2022 /PRNewswire/ -- IM Cannabis Corp. (the \"Company\" or \"IM Cannabis\") (CSE: IMCC, NASDAQ: IMCC), a leading medical and adult-use recreational cannabis company with operations in Israel, Canada, and Germany, has rescheduled the release of its operational and financial results for the fourth quarter and full year ended December 31, 2021, to before market open on Thursday, March 31, 2022.\n \n \nManagement will host a conference call to discuss the results, followed by a question-and-answer session from participants. To participate, please use the following information: \nQ4 and Full Year 2021 Conference Call Date: Thursday, March 31, 2022Time: 9:00 a.m. Eastern time (6:00 a.m. Pacific time)U.S./Canada Dial-in: 1-855-327-6837Israel Dial-in: 1-809-458-327Germany Dial-in: : 0-800-180-1954International Dial-in: 1-631-891-4304Conference ID: 10018676\nPlease dial in at least 10 minutes before the start of the call to ensure timely participation.\nA playback of the call will be available through Thursday, April 28, 2022. To listen, call 1-844-512-2921 within the United States or Canada or 1-412-317-6671 when calling internationally and enter replay pin number 10018676. A recording of the conference call will also be available on the events & presentations section of the IM Cannabis investor relations website linked here.\nAbout IM Cannabis Corp.\nIM Cannabis (NASDAQ: IMCC, CSE: IMCC) is a leading international cannabis company providing premium products to medical patients and adult-use recreational consumers. IM Cannabis is one of the very few companies with operations in Israel, Germany and Canada, the three largest federally legal markets. The ecosystem created through its international operations leverages the Company's unique data-driven perspective and product supply chain globally. With its commitment to responsible growth and financial prudence and ability to operate within the strictest regulatory environments, the Company has quickly become one of the leading cultivators and distributors of high-quality cannabis globally. \nThe IM Cannabis ecosystem operates in Israel through its commercial relationship with Focus Medical Herbs Ltd. (\"Focus Medical\"), which cultivates, imports and distributes cannabis to medical patients, leveraging years of proprietary data and patient insights. ...